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P reeclampsia remains a major problem worldwide for mothers and babies. It is estimated that yearly 50 000 women die in developing countries from preeclampsia. 1 Careful maternal observation for the signs of preeclampsia and delivery of women with increasingly severe preeclampsia is the cornerstone of management (as it has been for the past 100 years). Maternal mortality is, therefore, much less in developed countries with the capacity for careful perinatal observation, but morbidity is considerable and remains the leading cause of admissions to intensive care for pregnant women. 2 Also, the appropriate delivery of women who develop increasingly severe preeclampsia early in gestation accounts for 8% of all preterm births. 3 
Why No Advances in Clinical Management?
During the past 20 years, there has been an explosion in our knowledge of preeclampsia. The recognition of inflammation, including endothelial dysfunction as potential unifying pathophysiological concepts and the appreciation of the multisystemic nature of preeclampsia, has directed attention away from blood pressure as the sole or even most important pathophysiological issue of preeclampsia. 4 This concept has resulted in recognition of other origins of organ dysfunction. Despite this, we have not managed to affect the management or early recognition of preeclampsia with this information. Large, well-designed multicenter, clinical intervention trials have, at best, demonstrated a minimal effect on outcome except in perhaps the highest risk cases. Attempts to use factors implicated in the pathophysiology of the disorder to predict preeclampsia have also not as yet provided adequate sensitivity and specificity to be adopted for use in routine clinical practice.
is often interpreted as a result of publication bias. However, an alternative explanation is that the important difference between small and large studies is that small studies are usually within homogeneous populations, whereas large multicenter studies include a much more heterogeneous group of women. Furthermore, another explanation for the poor predictive power of studies guided by proposed pathogenic factors is that none of these factors can be demonstrated in all women with preeclampsia ( Figure S1 in the online-only Data Supplement). These findings lead to the hypothesis that not all preeclampsia is the same, that subtypes may be present. This is supported by clinical and epidemiological data. Most preeclampsia occurs in the last month of pregnancy; however, the 10% of earlier cases are strikingly different than those occurring at term. The excess of small for gestational age deliveries that occurs in preeclampsia is associated with disease presenting before 37 weeks of gestation when preeclampsia tends to be more severe. 6 Epidemiological data indicate major differences in the risk of later life cardiovascular disease with the risk with earlier onset preeclampsia 8-to 10-fold 7, 8 versus a doubling when preeclampsia occurs close to term. 9 A similar increased cardiovascular risk is present with recurrent preeclampsia. Clinically, preeclamptic women at any gestational age may present with fulminant preeclampsia that goes from recognition to life-threatening disease over hours to days or the syndrome may be indolent with little progression in the same time frame.
This hypothesis predicts that no 1 test will predict and no 1 treatment will prevent preeclampsia. However, to offer encouragement, this also means that if we could identify subtypes of preeclampsia, appropriate predictors could more successfully predict, and the appropriate treatment more effectively prevents the different subtypes of preeclampsia.
What Should We Do Differently?
Study designs that aggregate what might be different forms of preeclampsia, resulting from different pathophysiological pathways, are part of the problem. Amalgamation of the less obvious heterogeneous phenotypes is compounded by studies that combine obviously dissimilar subsets. Considering all causes of increased risk of preeclampsia as resulting in a group of homogeneous high-risk subjects is one such obvious error. Should it be surprising that a preeclamptic woman with a large placenta, as present with multiple gestations or diabetes mellitus, would not respond to the same preventive therapy as a woman with chronic hypertension or previous preeclampsia? Also important differences between recurrent and first pregnancy preeclampsia are often ignored and early and late onset preeclampsia are usually combined for analysis. Another discrimination, the difference between preeclampsia with proteinuria and gestational hypertension with no obvious systemic changes is often not made. It is likely that some cases of gestational hypertension are early preeclampsia. It is also possible that others reflect chronic hypertension, masked in early pregnancy by the physiological decrease in blood pressure that occurs at that time. Gestational hypertension without systemic involvement could also be a distinct and unrelated phenotype. In most settings, the findings with gestational hypertension are intermediate between normal pregnancy and preeclampsia. However, the increasing certainty that gestational hypertension is not a manifestation of a multisystemic syndrome (absence of hyperuricemia and markers of endothelial dysfunction) suggests that it generally is of more benign origin with outcomes for mother and baby not different than in normal pregnancy. 10, 11 There may, therefore, be a form of new onset hypertension in pregnancy, which has minimal effect on mother or baby.
The capacity to recognize and to exploit different subtypes is of obvious importance for prediction, prevention, and treatment. As an analogy, our progress in the successful management of diabetes mellitus would have been far less if all patients with carbohydrate intolerance were thought to be insulinopenic.
What Might Be the Subtypes of Preeclampsia?
Obvious subtypes of preeclampsia are early and late onset, recurrent and nonrecurrent, and preeclampsia with the different types of high-risk pregnancies. Clinically it is also possible that severe and mild preeclampsia and preeclampsia with and without intrauterine growth restriction could be different (see online-only Data Supplement). In addition, preeclampsia seems to have a different target in different cases. The primary organ involvement may be hepatic, renal, cardiovascular, or placental. Do these define different subtypes in which prediction and prevention may require different strategies?
Another interesting subclassification could exploit the differences in pathophysiological biomarkers associated with preeclampsia. In this regard, the most valuable findings would be those present before clinically evident disease. Once disease is established, the biochemical consequences of multiple organ involvement will mask causal pathways. However, we know that not all subjects manifest the same early markers, so should we begin to redefine preeclampsia on the basis of, for example, inflammatory, antiangiogenic, oxidative stress, or endoplasmic stress-mediated subtypes? Some caution is required here, however, because some biochemical clusters may reflect different steps in a common pathway. Nonetheless, the common strategy of amalgamating all is increasingly undermined by the current evidence base. To achieve progress in prediction and prevention inevitably demands recognition of subtypes (see online-only Data Supplement). Although the hypothesis of several subtypes of preeclampsia to explain the discrepant findings and outcomes in preeclampsia is attractive, it has also recently been proposed that true preeclampsia is only present when excess antiangiogenic or deficient angiogenic factors are present. Without these findings, preeclampsia is a misdiagnosis. 12 The argument is that the most dangerous features of new onset gestational hypertension with proteinuria or other organ involvement are much more common when angiogenic imbalance is evident from laboratory findings. These abnormal angiogenic findings are also more prevalent in early onset, the most serious form of this disorder. To a certain extent this concept is not without potential risk if applied to current clinical practice. Most deaths from preeclampsia are in developing countries with late onset preeclampsia, which is less likely to be accompanied by these laboratory findings, Nonetheless the understanding of preeclampsia regardless of semantics will be aided by more standardized definitions and data and biological sample collection.
It is with this goal of translating current and emerging understanding to define, treat, and prevent disease that we make the following proposal for the investigation of preeclampsia.
Proposal Appreciation of Preeclampsia as a Syndrome
The current definition of preeclampsia requires renal (proteinuria) and cardiovascular (blood pressure) dysfunction. These were established historically as the first signs preceding what at the time was considered a pregnancy-specific seizure disorder, eclampsia. 13 They were not selected as sensitive or specific indicators of maternal or fetal morbidity. However, in combination they predict increased risk for mother and baby and indicate that preeclampsia affects many organ systems. This is confirmed by the increased risk associated with gestational hypertension when accompanied by other systemic involvement, even without proteinuria. [14] [15] [16] Thus, a key feature in studying preeclampsia is recognizing the fact that it is a syndrome and that it can occur in the absence of proteinuria.
Identification of Preeclampsia Subtypes
Identifying possible preeclampsia subtypes is clearly an important goal in translating findings of preeclampsia research into effective modifications of clinical care. We have presented obvious candidates. How do we modify current research strategies to address this goal? Either we must examine homogenous groups of women-only nulliparas, only obese women, only women with previous preeclampsia, only early onset preeclampsia, etc-or the study population should be of an adequate size to enable separate study of these obviously different groups. There should, at the very least, be an effort to look at results in relation to these different possible subtypes (and allow readers to also make these comparisons), given the problems of inadequate power in smaller studies. The solution to this quandary is big science that is the merging of data and biological samples from several centers. This is a major goal of the Global Pregnancy CoLaboratory, which has authored this article because data and biosample sharing can only be successful with standardized data and sample collection.
We present a strategy for research to study preeclampsia and suggest that further large multicenter trials be deferred until rigorous exploration for subtypes of preeclampsia has been attempted.
Approach
Comparisons and interpretation of the data generated in the many studies of preeclampsia remain complicated because of differences in study sizes, study designs, definition of patient groups, and outcomes measured. There is a need for standardization of study design, including patient selection, data collection, and definition of outcome, to allow comparable studies and trials to be performed and allow comparison of data sets and integration for meta-analyses. To facilitate comparison of studies or trials, at a minimum, the patient groups selected, information collected, and definitions used need to be similar. Critical components of this approach are unambiguous and unbiased definitions. With this in mind, we recommend collecting the clinical and laboratory information necessary to make the diagnosis that is then examined retrospectively in a blinded manner by impartial observers rather than relying on clinical diagnoses made by care providers.
We offer here an outline that can be used for study design and clinical trials. We also present what we think are the minimum requirements for a data set in a study of preeclampsia that will facilitate comparisons (Table 1) . Subsequently, we define a comprehensive or optimal data set ( Table 2) together with recommendations for collection of biological materials (Table 3) . This, we consider, would provide all that is needed for in-depth investigation of pathophysiology.
Key Definitions
For studies to be relevant to current clinical practice, the definition of preeclampsia can be that currently used and accepted. However, diagnostic criteria change. Thus, sufficient data should be collected (Tables 1 and 2 ) to allow retrospective analysis not only to satisfy new diagnostic recommendations but also to facilitate the development of novel and improved methods of diagnosis (see online-only Data Supplement). Defining the syndrome by only traditional criteria is too limited and does not facilitate progress.
Gestational Age
Gestational age should be determined using information from the last menstrual period, if known, and first or second trimester ultrasounds with standardized criteria for resolving discrepancies between menstrual history and ultrasound findings 17 or, if last menstrual period is not known, preferably by first trimester ultrasound (Table S1 , online-only data supplement). Gestational age should be recorded by completed weeks and days.
Fetal Variables
A proportion of pregnancies complicated by preeclampsia is also associated with intrauterine growth restriction. In all cases, birth weight and gestational age data should be recorded to determine whether the fetus is small for gestational age. Population-specific birth weight centiles adjusted for gestational age, ethnicity, and sex should be calculated.
Control Subjects Mechanistic Studies
Parity, age, race, ethnicity, smoking, and body mass index are all recognized to influence the incidence of preeclampsia and patients in case control studies should, therefore, be carefully matched for each of these factors. Also, in these studies, it is appropriate to compare women with preeclampsia with women with normal outcomes to identify the specific pathophysiology of preeclampsia. In case control studies, case and controls should be matched for gestational age and parity.
Prediction Studies
For studies of predictors, it is not appropriate to compare women with preeclampsia with women with normal outcomes. This will inevitably falsely enhance the predictive capability. When a predictive test is used in the real world, it will attempt to identify women with preeclampsia as distinct from all other outcomes, both normal and abnormal. Therefore, the use of the test in this scenario should always be evaluated. Any information not known at the times of testing (eg, eventual pregnancy outcome) must not influence the selection of controls. It is equally inappropriate to combine high-and low-risk women in a prediction study; populations should be predefined according to the risk status. Eventually, after such trials of defined risk subjects, clinical data and biomarkers can be combined for prediction.
Clinical Trials

Low-Risk Subjects
Standardization of studies of low-risk subjects should use the following exclusion criteria at recruitment: Intrauterine fetal death (before admission/after admission)
Neonatal death
Gestational age at delivery in completed weeks and days (if possible; calculated as in Table S1 using LMP and ultrasound)
Sex
Newborn weight BMI indicates body mass index; BP, blood pressure; GDM, gestational diabetes mellitus; HELLP, hemolysis elevated liver enzymes low platelets; IUGR, intrauterine growth restriction; LMP, last menstrual period; PC, protein/creatinine; PIH, pregnancy-induced hypertension; and SGA, small for gestational age. 2. Proteinuria as exhibited by either of the following: a. A spot urine protein/creatinine ratio of >30 mg/mmol at any time during this pregnancy. b. A 24-hour urine collection of ≥300-mg protein, or the equivalent from a timed collection, at any time during this pregnancy. (Dipstick protein values should not be used unless no other measurement is available, then two readings of 1+ would exclude the individual) 3. History or current use of antihypertensive medication (including diuretics). 4. Pregestational diabetes mellitus 5. Current pregnancy as a result of in vitro fertilization. 6. Regular use (more than once a week) of platelet active drugs (eg, heparin) or nonsteroidal anti-inflammatory agents affecting platelet activity (eg, ibuprofen, aspirin, Cox-1 and Cox-2 inhibitors). The use of platelet active drugs or nonsteroidal anti-inflammatory agents affecting platelet activity within 7 days (168 hours) before randomization for all studies. 7. Known fetal abnormalities (eg, neural tube defect), known chromosomal or major malformations, fetal demise, or planned termination. 8. Documented uterine bleeding within a week of screening. Unobserved self-reported bleeding with confirmed intact pregnancy on ultrasound after the bleeding episode is not an exclusion. 9. Uterine malformations Appendix for other important information BPD indicates bronchopulmonary dysplasia; CD4, cluster of differentiation 4; CHD, coronary heart disease; FGR, fetal growth restriction; HELLP, hemolysis elevated liver enzymes low platelets; ICSI, intra-cytoplasmic sperm injection; IUGR, intrauterine growth restriction; IVF, in vitro fertilization; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PCOS, polycystic ovary syndrome; RDS, respiratory distress syndrome; SGA, small for gestational age; STD, sexually transmitted disease; SSRI, selective serotonin reuptake inhibitor; Vit, vitamin; and TB, tuberculosis. 
High-Risk Subjects
Studies of women who are at high risk for development of preeclampsia should be sufficiently powered to determine the efficacy of therapy or prediction on obviously disparate risk groups separately.
Confounding Factors to be Considered in All Studies Obesity
Obesity has a profound effect on the incidence of preeclampsia with the incidence typically doubling with each 5 to 7 kg/m 2 increase in prepregnancy body mass index. 18 Indeed the dramatic increase in obesity in the United States for the past 10 years means that obesity has become a major pathophysiologic factor, probably via its associated inflammatory milieu, in the development of preeclampsia. Because obesity is also more prevalent in black and Hispanic populations, it needs to be taken into account as a confounding factor in studies. If possible, prepregnancy body mass index should be recorded together with body mass index in the first trimester and at delivery. Weight gain throughout pregnancy should be calculated.
Smoking
The incidence of smoking is decreasing slowly in the United States but varies by region and by socioeconomic status. Paradoxically smoking exerts a protective effect on the development of preeclampsia 19 although preeclampsia that develops in smokers is usually more severe. Data on whether the patient was ever or never a smoker should be obtained as well as whether the patient smoked during the index pregnancy.
Sex of the Fetus
There is a strong influence of sexual dimorphism across many aspects of reproductive physiology, particularly those involving inflammatory mechanisms. There is a well-known association of a male fetus with adverse perinatal outcomes, particularly those related to delivery at early gestational age. 20 The presence of a male fetus (and a male placenta) is associated with a slightly greater overall risk (1.02) of development of preeclampsia than that of a female fetus. 20 However, preeclampsia that develops early in gestation is predominantly more associated with a female rather than that with a male fetus (relative risk, 0.7 at 26 weeks). 20 Whether this effect is because of a disproportionate delivery of male fetuses for other causes at this time that removes them from the population that will develop preeclampsia remains unknown. However, the presence of a sexually dimorphic effect means fetal sex should be recorded.
Outcomes
The outcome variables recorded for studies will be dependent on whether the study is a clinical trial of an intervention or whether it is a study evaluating a predictor. In addition, for clinical intervention studies, demographic factors will influence the outcome studied. In developing countries, the focus is on maternal outcomes, whereas in developed countries the focus will be more on fetal outcomes. With this in mind outcomes on both mother and fetus should be collected, and composite outcomes combining fetal and maternal outcomes are discouraged.
Standardized Data Collection
The value and strength of any clinical study is proportional to the amount and quality of data collected. We provide in Table 1 the minimum data set we consider necessary for collection in a study of preeclampsia. This would allow combination and comparison with other data sets to enable meta-analyses to be performed. In Table 2 , we provide the optimal data set that could be collected in a comprehensive approach when studies involving determination of pathophysiologic mechanisms are proposed. Guidelines for specifying date and time using International Standard ISO 8601 and for the use of SI units are presented in the in the online-only Data Supplement.
Perspective
Despite many years of clinical and basic science studies and of many small-scale and several large-scale interventional studies, we have not been able to predict, prevent, or treat preeclampsia. There is now a growing realization that under the umbrella of the preeclampsia syndrome, there may be several different phenotypes that may be predicted by distinct biomarkers, presented with different features, and potentially treated by different therapies. Previously, using a standard clinical definition of preeclampsia, these phenotypes have been merged within large cohorts contributing to the lack of success in predicting and treating preeclampsia. The lack of standardization in study design and clinical data acquisition has prevented combination of studies. We offer here an outline that can be used for study design and clinical trials. In addition, we present the minimum requirements for a data set that will facilitate comparisons, whereas collection of a more comprehensive or optimal data set will allow in-depth investigation of pathophysiology. We are now at the point of being able to define phenotypes of preeclampsia by clinical and biochemical criteria and thus tremendously increase our understanding of pathophysiology. Knowledge of distinct pathophysiologies will to lead to more specific therapeutic approaches.
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